The mechanism of action of bevacizumab is that by binding to VEGF, it prevents VEGF from binding to its natural receptor, VEGFR, and inhibits the proliferation and activation of vascular endothelial cells, so as to exert anti-angiogenesis and anti-tumor effects (86, 87). This evidence concerns the gene KDR and neoplasm.